Impact of CD34 positive cell dose in donor graft on the outcomes after haploidentical peripheral blood stem cell transplantation with post-transplant cyclophosphamide – A retrospective single-center study with a Japanese cohort

IF 2.1 4区医学 Q3 HEMATOLOGY

Blood Cells Molecules and Diseases Pub Date : 2023-12-30 DOI:10.1016/j.bcmd.2023.102820

Yumiko Maruyama , Hidekazu Nishikii , Naoki Kurita , Tatsuhiro Sakamoto , Keiichiro Hattori , Yasuhito Suehara , Yasuhisa Yokoyama , Takayasu Kato , Naoshi Obara , Mamiko Sakata-Yanagimoto , Shigeru Chiba

{"title":"Impact of CD34 positive cell dose in donor graft on the outcomes after haploidentical peripheral blood stem cell transplantation with post-transplant cyclophosphamide – A retrospective single-center study with a Japanese cohort","authors":"Yumiko Maruyama , Hidekazu Nishikii , Naoki Kurita , Tatsuhiro Sakamoto , Keiichiro Hattori , Yasuhito Suehara , Yasuhisa Yokoyama , Takayasu Kato , Naoshi Obara , Mamiko Sakata-Yanagimoto , Shigeru Chiba","doi":"10.1016/j.bcmd.2023.102820","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p><span>Haploidentical peripheral blood stem cell transplantation<span> (haplo-PBSCT) with post-transplant cyclophosphamide<span> (PTCy) is an important therapeutic option for patients lacking an HLA-matched donor. However, the significance of CD34</span></span></span><sup>+</sup> cell dose in grafts has not been fully elucidated.</p></div><div><h3>Objective</h3><p>We aimed to explore the impact of CD34<sup>+</sup> cell dose on outcomes after haplo-PBSCT with PTCy.</p></div><div><h3>Study Design</h3><p>We retrospectively investigated 111 consecutive patients who underwent haplo-PBSCT with PTCy or HLA-matched PBSCT from related donors.</p></div><div><h3>Results</h3><p>There were no statistically significant differences in 3-year overall survival (<em>p</em> = 0.559) or progression-free survival (<em>p</em><span> = 0.974) between haplo-PBSCT and matched PBSCT. Delayed neutrophil<span> engraftment and a lower incidence of graft-versus-host disease were observed in haplo-PBSCT. The median dose of CD34</span></span><sup>+</sup> cells was 4.9 × 10<sup>6</sup> /kg in 57 haplo-PBSCT and 4.5 × 10<sup>6</sup> /kg in 54 matched PBSCTs. Importantly, patients who underwent haplo-PBSCT with the administration of CD34<sup>+</sup> cell at a dose of ≥4.0 × 10<sup>6</sup> /kg significantly had improved OS (<em>p</em> = 0.015) and decreased incidence of disease relapse (<em>p</em> = 0.001) without increasing incidence of GVHD.</p></div><div><h3>Conclusion</h3><p>Our data suggest that a higher dose of CD34<sup>+</sup> cells in haplo-PBSCT with PTCy positively impacts the outcomes without an increase of GVHD.</p></div>","PeriodicalId":8972,"journal":{"name":"Blood Cells Molecules and Diseases","volume":"105 ","pages":"Article 102820"},"PeriodicalIF":2.1000,"publicationDate":"2023-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Blood Cells Molecules and Diseases","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1079979623000979","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Haploidentical peripheral blood stem cell transplantation (haplo-PBSCT) with post-transplant cyclophosphamide (PTCy) is an important therapeutic option for patients lacking an HLA-matched donor. However, the significance of CD34⁺ cell dose in grafts has not been fully elucidated.

Objective

We aimed to explore the impact of CD34⁺ cell dose on outcomes after haplo-PBSCT with PTCy.

Study Design

We retrospectively investigated 111 consecutive patients who underwent haplo-PBSCT with PTCy or HLA-matched PBSCT from related donors.

Results

There were no statistically significant differences in 3-year overall survival (p = 0.559) or progression-free survival (p = 0.974) between haplo-PBSCT and matched PBSCT. Delayed neutrophil engraftment and a lower incidence of graft-versus-host disease were observed in haplo-PBSCT. The median dose of CD34⁺ cells was 4.9 × 10⁶ /kg in 57 haplo-PBSCT and 4.5 × 10⁶ /kg in 54 matched PBSCTs. Importantly, patients who underwent haplo-PBSCT with the administration of CD34⁺ cell at a dose of ≥4.0 × 10⁶ /kg significantly had improved OS (p = 0.015) and decreased incidence of disease relapse (p = 0.001) without increasing incidence of GVHD.

Conclusion

Our data suggest that a higher dose of CD34⁺ cells in haplo-PBSCT with PTCy positively impacts the outcomes without an increase of GVHD.

查看原文本刊更多论文

供体移植物中 CD34 阳性细胞剂量对移植后环磷酰胺单倍体外周血干细胞移植结果的影响--一项以日本人为队列的单中心回顾性研究

背景单倍体外周血干细胞移植（haploidentical peripheral stem cell transplantation，haplo-PBSCT）与移植后环磷酰胺（post-transplant cyclophosphamide，PTCy）是缺乏HLA匹配供体患者的重要治疗选择。目的我们旨在探讨 CD34+ 细胞剂量对单倍体-PBSCT 和 PTCy 移植后预后的影响。研究设计我们回顾性研究了111例连续接受PTCy单倍体-PBSCT或HLA匹配的相关供者PBSCT的患者。结果单倍体-PBSCT与匹配的PBSCT在3年总生存期（p = 0.559）或无进展生存期（p = 0.974）方面无统计学差异。在单倍体骨髓造血干细胞移植中观察到中性粒细胞移植延迟和移植物抗宿主病的发生率较低。在57例单倍体-PBSCT和54例匹配的PBSCT中，CD34+细胞的中位剂量分别为4.9 × 106 /kg和4.5 × 106 /kg。重要的是，接受单倍体-PBSCT且CD34+细胞剂量≥4.0 × 106 /kg的患者的OS明显改善（p = 0.015），疾病复发率降低（p = 0.001），但GVHD发生率并未增加。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Blood Cells Molecules and Diseases 医学-血液学

CiteScore

4.90

自引率

0.00%

发文量

审稿时长

14 days

期刊介绍： Blood Cells, Molecules & Diseases emphasizes not only blood cells, but also covers the molecular basis of hematologic disease and studies of the diseases themselves. This is an invaluable resource to all those interested in the study of hematology, cell biology, immunology, and human genetics.